Global Lysosomal Storage Diseases Market 2017-2021

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research methodology

PART 04: Introduction

• Market outline

PART 05: Understanding LSDs

• Introduction

PART 06: Pipeline

PART 07: Market landscape

• Market overview
• Five forces analysis

PART 08: Market segmentation by therapy

• Enzyme replacement therapy (ERT)
• Substrate reduction therapy (SRT)
• Cystine depleting agents

PART 09: Market segmentation by geography

• Geographical segmentation
• LSDs market in EMEA
• LSDs market in Americas
• LSDs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

• Market drivers
• Market challenges

PART 12: Trends

• Advent of modern technologies
• Regulatory assistance in emerging nations
• Increased R&D activities
• Increased focus on gene therapy
• Emergence of immunotherapy
• Growing public awareness

PART 13: Vendor landscape

• Competitive scenario

PART 14: Key vendor analysis

• Actelion Pharmaceuticals
• BioMarin
• Genzyme
• Shire
• Other Prominent Vendors

PART 15: Appendix

• List of abbreviations